- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01661296
Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India
An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study location and participants: Subjects for this study were recruited among children between the ages of 1-17 and adults between the ages of 18-85 who visit the dermatology outpatient clinic at PBM Hospital, Bikaner, with suspected CL. Informed consent was obtained from adults or from parents/legal guardians of minors for procedures and inclusion in the study. Individuals with any uncontrolled chronic medical condition, breast feeding, on immunosuppressive drugs or anticipated unavailability for follow-up were excluded from the study. Patients with more than 4 lesions were also excluded.
Study procedures: The diagnosis of CL was established by clinical examination, history of residence in an L. tropica-endemic area, and by microscopic examination of Giemsa-stained lesion smears for parasites (Leishmania tropica bodies) or lesion biopsy. For patients who were both smear and skin biopsy negative, PCR was used to detect parasites in the lesion tissue. The lesion and surrounding skin were cleaned with stabilized 0.1% chlorine dioxide solution, and local anesthesia was administered by subcutaneous injection of 2% Lidocaine around the lesion. RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds using a current field radio-frequency generator (ThermoMed 1.8; Thermosurgery Inc. USA). Patients were be prescribed an oral NSAID and topical antimicrobial cream for 5 days. Cure of infection and any recurrence was monitored by clinical follow-up at days 10 and months 1, 2, 3, 4, 6, 9, 12 and 18 months post-treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Rajasthan
-
Bikaner, Rajasthan, India
- PBM Hospita and SP Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- parasitologically confirmed diagnosis of cutaneous leishmaniasis
Exclusion Criteria:
- Multiple lesions (more than 4)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sodium stibogluconate
Intralesional SSG was administered in dose of 50 mg cm -2 of lesion once a week for 6 weeks (total six injections)
|
Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
Other Names:
|
Active Comparator: RFH therapy
RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia (1% lidocaine) using a current field radio-frequency generator (ThermoMed 1.8, Thermosurgery Inc).
|
RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to heal lesion
Time Frame: 6 months after treatment
|
6 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tissue scarring
Time Frame: 12 months
|
12 months
|
Recurrence/Relapse of lesion
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ram A Bumb, MD, PBM Hospital and SP Medical College, Bikaner, Rajasthan, India
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Skin Diseases, Parasitic
- Skin Diseases, Infectious
- Euglenozoa Infections
- Leishmaniasis
- Leishmaniasis, Cutaneous
- Anti-Infective Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Antimony Sodium Gluconate
Other Study ID Numbers
- SPMC/09/10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Leishmaniasis
-
Medecins Sans Frontieres, NetherlandsUnknownOld World Cutaneous Leishmaniasis
-
Drugs for Neglected DiseasesWellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable...CompletedVisceral Leishmaniasis | Cutaneous LeishmaniasesUnited Kingdom
-
Hospital Universitário Professor Edgard SantosOswaldo Cruz Foundation; Conselho Nacional de Desenvolvimento Científico e...CompletedCutaneous Leishmaniasis, AmericanBrazil
-
Fundacion Nacional de DermatologiaHospital Dermatologico de Jorochito; Ministerio de Salud de Bolivia, Programa... and other collaboratorsCompletedCutaneous Leishmaniasis, AmericanBolivia
-
Centro Internacional de Entrenamiento e Investigaciones...University of TexasCompletedCutaneous Leishmaniasis (Diagnosis)Colombia
-
Knight Therapeutics (USA) IncCompletedCutaneous Leishmaniasis | Mucosal LeishmaniasisUnited States
-
Hospital Universitário Professor Edgard SantosInstituto Gonçalo Muniz FIOCRUZ BANot yet recruitingCutaneous Leishmaniasis, AmericanBrazil
-
Centro Internacional de Entrenamiento e Investigaciones...Universidad IcesiCompletedCutaneous Leishmaniasis, AmericanColombia
-
University of BrasiliaCompletedLocalized Cutaneous LeishmaniasisBrazil
-
U.S. Army Medical Research and Development CommandCompletedOld World Cutaneous LeishmaniasisTunisia
Clinical Trials on Sodium stibogluconate
-
Northwestern UniversityRobert H. Lurie Cancer CenterTerminatedMyelodysplastic SyndromesUnited States
-
First Affiliated Hospital of Jinan UniversityRuijin HospitalRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | P53 Mutation | Myeloid Malignancy | Temperature-Sensitive p53 Mutation | Sodium StibogluconateChina
-
Waisenmedizin e. V. Promoting Access to Essential...University of Erlangen-Nürnberg Medical School; German Federal Ministry of... and other collaboratorsCompletedWound HealingAfghanistan
-
U.S. Army Medical Research and Development CommandWalter Reed Army Medical CenterCompleted
-
University of California, San FranciscoNo longer availableLeishmaniasis, Cutaneous | Leishmaniasis, MucocutaneousUnited States
-
U.S. Army Medical Research and Development CommandWalter Reed Army Medical CenterCompleted
-
U.S. Army Medical Research and Development CommandWalter Reed Army Medical CenterCompletedCutaneous LeishmaniasisUnited States
-
University of YorkUniversity of Khartoum; Makerere University; European and Developing Countries... and other collaboratorsRecruitingVisceral LeishmaniasisKenya
-
Drugs for Neglected DiseasesNovartis PharmaceuticalsRecruitingPrimary Visceral LeishmaniasisEthiopia
-
Drugs for Neglected DiseasesCompletedVisceral LeishmaniasisKenya, Ethiopia, Sudan, Uganda